Quest Diagnostics Incorporated Stock News

Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.

Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business.

Quest Diagnostics' (DGX) latest partnership will increase the likelihood that Americans will eventually have an easy, reliable and accessible way to check for colorectal cancer.

Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing with the launch of Quest Mobile.

Quest Diagnostics' (DGX) base business growth reflects the company's ongoing efforts to partner with health plans, hospitals and physicians amid a continued return to care.

Quest Diagnostics (DGX) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.36 per share a year ago.

Quest Diagnostics Inc. DGX, -1.84% said Tuesday its third-quarter profit dropped by 12.2% to $225 million, or $1.96 a share, from $256 million, or $2.17 a share, in the year-ago quarter. Adjusted thir

Quest Diagnostics (DGX) third-quarter 2023 results are likely to reflect continued strength in the base business.

Quest Diagnostics' (DGX) recent acquisition of New York-Presbyterian's outreach assets adds to volume growth within Physician Lab Services.

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

Quest Diagnostics (DGX) latest deal will boost dialysis laboratory testing and reduce the laboratory costs of dialysis programs for ESRD patients.

SECAUCUS, N.J. , Oct. 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Investors are optimistic about Quest Diagnostics (DGX), backed by collaborations with health plans and upbeat guidance.

Quest Diagnostics (DGX) and Americares will provide 10 clinics with no-cost diagnostic services for a year to help patients manage chronic disease.